CVRX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

15.57M

+1.5%

-0.444

+3.34%

14.38M

+16.49%

-0.500

-5.66%

15.78M

+16.09%

-0.490

-14.04%

Estimates Revision

The market is revising No Change the revenue expectations for CVRx, Inc. (CVRX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -11.03%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-11.03%

In Past 3 Month

5 Analyst Rating

Wall Street analysts forecast CVRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CVRX is 12.67 USD with a low forecast of 11.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

11.00

Averages

12.67

High

14.00

Current: 0.000

Low

11.00

Averages

12.67

High

14.00

Canaccord

Buy

upgrade

$9 -> $11

2025-11-06

Reason

Canaccord

Price Target

$9 -> $11

2025-11-06

upgrade

Buy

Reason

Canaccord raised the firm's price target on CVRx to $11 from $9 and keeps a Buy rating on the shares. The firm said they reported Q3 results ahead of expectations and they believe that the company is beginning to become confident about its rep hires beginning to become productive, which it attributed to the Q3 performance but still expects the bulk of the benefit to be realized in 2026.

Cantor Fitzgerald

Ross Osborn

Overweight

maintain

$11 -> $13

2025-11-06

Reason

Cantor Fitzgerald

Ross Osborn

Price Target

$11 -> $13

2025-11-06

maintain

Overweight

Reason

Cantor Fitzgerald analyst Ross Osborn raised the firm's price target on CVRx to $13 from $11 and keeps an Overweight rating on the shares. The company reported "strong" Q3 operating results and narrowing guidance, the analyst tells investors in a research note.

JPMorgan

Neutral -> Underweight

downgrade

$15 -> $7

2025-05-09

Reason

JPMorgan

Price Target

$15 -> $7

2025-05-09

downgrade

Neutral -> Underweight

Reason

JPMorgan downgraded CVRx to Underweight from Neutral with a price target of $7, down from $15. The company reported a miss in Q1 as the planned salesforce reorganization led to greater than expected turnover and account disruption, the analyst tells investors in a research note. The firm says continued uncertainty around potential rate changes in the proposed outpatient prospective payment system come July and "choppiness" in sales growth trends is leading to significant uncertainty around CVRx's trajectory to cash flow breakeven.

Piper Sandler

Matt O'Brien

Overweight

downgrade

$20 -> $12

2025-05-09

Reason

Piper Sandler

Matt O'Brien

Price Target

$20 -> $12

2025-05-09

downgrade

Overweight

Reason

Piper Sandler analyst Matt O'Brien lowered the firm's price target on CVRx to $12 from $20 and keeps an Overweight rating on the shares. The firm notes the company reported Q1 results that were in line with the pre-announcement. Management primarily attributed the miss to sales force realignment that was more substantial than initially anticipated. CVRx also lowered full year sales guidance by more than the miss in the quarter. Piper believes the new guidance is fairly set but there is no lay-up as it still anticipates some productivity improvement through year-end.

Canaccord Genuity

William Plovanic

Strong Buy

Maintains

$23 → $18

2025-04-08

Reason

Canaccord Genuity

William Plovanic

Price Target

$23 → $18

2025-04-08

Maintains

Strong Buy

Reason

Canaccord lowered the firm's price target on CVRx to $18 from $23 and keeps a Buy rating on the shares. The firm updated its model to reflect both the Q1/25 revenue miss and a lower outlook for the US given the sales force disruption. They also expect the company to continue to invest in growth and therefore operating expenses will stay similar to pre-release estimates.

Lake Street

Frank Takkinen

Strong Buy

Maintains

$19 → $14

2025-04-08

Reason

Lake Street

Frank Takkinen

Price Target

$19 → $14

2025-04-08

Maintains

Strong Buy

Reason

Lake Street analyst Frank Takkinen lowered the firm's price target on CVRx to $14 from $19 and keeps a Buy rating on the shares after the company announced preliminary Q1 revenue that fell short of expectations. The firm believes the shortfall was "the result of natural growing pains, not structural roadblocks," the analyst tells investors. The firm, which also believes the company continues to have adequate liquidity, notes that the company does not expect a material tariff impact.

Valuation Metrics

The current forward P/E ratio for CVRx Inc (CVRX.O) is -3.74, compared to its 5-year average forward P/E of -6.07. For a more detailed relative valuation and DCF analysis to assess CVRx Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.07

Current PE

-3.74

Overvalued PE

-3.38

Undervalued PE

-8.76

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-5.71

Current EV/EBITDA

-3.55

Overvalued EV/EBITDA

0.11

Undervalued EV/EBITDA

-11.53

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

7.29

Current PS

2.98

Overvalued PS

12.10

Undervalued PS

2.47

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

CVRX News & Events

Events Timeline

No data

News

2.0

2025-11-06NASDAQ.COM

Medtech Stocks Surge in After-Hours Trading: RxSight, Penumbra, and Evolus Take the Lead

7.0

2025-07-16Newsfilter

CVRx Announces Positive News on Outpatient Payment for Barostim

1.0

2025-05-28Newsfilter

CVRx to Present at the William Blair 45th Annual Growth Stock Conference

People Also Watch

Frequently Asked Questions

What is CVRx Inc (CVRX) stock price today?

The current price of CVRX is 8.15 USD — it has decreased -3.55 % in the last trading day.

What is CVRx Inc (CVRX)'s business?

CVRx, Inc. is a commercial-stage medical device company. The Company is focused on developing, manufacturing and commercializing advanced neuromodulation solutions for patients with cardiovascular diseases. The Company's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programmed by a wireless clinician-controlled programmer that communicates with the IPG.

What is the price predicton of CVRX Stock?

What is CVRx Inc (CVRX)'s revenue for the last quarter?

CVRx Inc revenue for the last quarter amounts to 14.69M USD, increased 9.85 % YoY.

What is CVRx Inc (CVRX)'s earnings per share (EPS) for the last quarter?

CVRx Inc. EPS for the last quarter amounts to -0.49 USD, decreased -14.04 % YoY.

What changes have occurred in the market's expectations for CVRx Inc (CVRX)'s fundamentals?

How many employees does CVRx Inc (CVRX). have?

CVRx Inc (CVRX) has 206 emplpoyees as of January 09 2026.

What is CVRx Inc (CVRX) market cap?

Today CVRX has the market capitalization of 221.48M USD.